Boehringer Ingelheim Advances Collaboration with Salipro Biotech by Exercising Option

Salipro Biotech AB announced today that Boehringer Ingelheim has exercised its option for a Salipro®-enabled target under the Research and License Agreement signed earlier this year. This step marks an important progression in the collaboration aimed at enabling novel drug discovery through Salipro Biotech’s proprietary membrane protein stabilization technology.

This progress is the direct result of excellent teamwork from both sides. By working together to unlock challenging drug targets, the teams are successfully integrating the Salipro® platform into Boehringer Ingelheim’s research programs supporting the development of novel therapeutic solutions.